Federal Judge Revives Pharma Patent Claims in Landmark Delaware Court Ruling

In a recent legal development from the District of Delaware, a federal judge has ruled to reinstate patent claims previously deemed invalid. The case involves HQ Specialty Pharma Corp., which accused Fresenius Kabi of infringing on its injectable calcium supplement patent. The judge’s decision allows HQ Specialty to amend their patent claims, which subsequently impacted their validity status. This ruling marks a critical point in the patent infringement litigation between the two pharmaceutical entities. For further details, the full narrative is available through Law360.